Equities
  • Price (CHF)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

CONMED Corporation is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company is focused on advancing the healing of soft tissue using its proprietary BioBrace Implant technology. The Company's product lines consist of orthopedic surgery and general surgery. Its orthopedic surgery consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgery procedures including dissociated horizontal deviation (DHD) and DHD vision technologies. Its general surgery consists of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, a line of cardiac monitoring products, as well as electrosurgical generators and related instruments. Its products used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology and gastroenterology.

  • Revenue in USD (TTM)1.07bn
  • Net income in USD-82.72m
  • Incorporated2020
  • Employees3.80k
  • Location
    Conmed Corp11311 Concept BoulevardLARGO 33773United StatesUSA
  • Phone+1 (727) 214-2974
  • Fax+1 (302) 655-5049
  • Websitehttps://www.conmed.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
CNMD:NYQ since
announced
Transaction
value
Biorez IncDeal completed01 Aug 202201 Aug 2022Deal completed-12.10%250.00m
In2Bones Global IncAnnounced04 May 202204 May 2022Announced-36.13%255.00m
Data delayed at least 15 minutes, as of Dec 06 2022 21:10 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.